If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Menu closed
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Taltz ® (ixekizumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Taltz Summary of Product Characteristics (SmPC)
Taltz® (ixekizumab): Air bubbles
Air bubbles in the pre-filled pen and the pre-filled syringe are normal. They will not harm the user or affect the dose.
Further
information
It
is normal to sometimes see an air bubble / air bubbles in the Taltz
device. Taltz is injected under the skin (subcutaneous injection).
Air bubbles are not a problem in this type of injection. They will
not harm the user or affect the dose.1
The
air bubble is a normal part of the syringe manufacturing process for
Taltz devices.2
The
user should not try to remove or expel the air bubble in the device.
Removal of the air bubble before injecting is not necessary and not
recommended. Doing so can affect the dose.2
References
1.
Taltz EU Patient Information Leaflet – Instructions for Use,
Utrecht, The Netherlands: Eli Lilly Nederland B.V.
2.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review:November 05, 2020
Are you satisfied with this content?
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com